Ancillary MRI/CT studies may be performed as clinically indicated. 
14.0 TOXICITY MONITORING 
14.1 Toxicity will be monitored and graded according to the NCI Common Toxicity 
Criteria as listed in Appendix C. 
14.2 A post ABMT hematologic recovery score based on the Dartmouth Transplant 
Criteria will be assigned to all patients. 
Score 
0 PMNs never <500/ul, platelets never <10,000/ul 
1 PMNs >500, platelets > 10,000 within 4 weeks of ABMT 
2 PMNs >500, platelets >10,000 within 4-8 weeks post ABMT 
3 PMNs >500, platelets >10,000 beyond 8 weeks post ABMT 
4 Death due to bacterial or fungal infection, or hemorrhage associated 
with PMNs < 500/ul, platelets <10,000/ul more than 8 weeks post 
ABMT. 
15.0 RECORDS TO BE KEPT 
Flow sheets documenting dates and doses of therapy as well as clinical chemistries, 
hematologic parameters, the clinical status and occurrence of any adverse events and 
subsequent interventions are to be kept on all patients. 
Radiographic reports 
Surgical summaries 
Autopsy summaries, where appropriate 
Date of entry on to other appended protocols 
Informed consent documents 
16.0 INFORMED CONSENT 
All patents and/or their legsil guardian must sign a document of informed consent 
consistent with local institutional and Federal guidelines stating that they are aware 
of the investigational nature of this protocol and giving an account of the possible side 
effects of treatment. Further, patients must be informed that no efficacy of this 
therapy is guaranteed, and that unforseen toxicides may occur. Patients have the right 
Recombinant DNA Research, Volume 14 
[729] 
